Last reviewed · How we verify
NCT06629831
Systemic Inflammatory Biomarkers in Ovarian Cancer
trial testing group with complications in Ovarian Cancer in 90 participants. Completed in 27 September 2024.
1 December 2023
Quick facts
| Lead sponsor | Bakirkoy Dr. Sadi Konuk Research and Training Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 90 |
| Start date | 1 December 2022 |
| Primary completion | 1 December 2023 |
| Estimated completion | 27 September 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- group with complications
- group without complications
Conditions studied
- Ovarian Cancer — all drugs for Ovarian Cancer →
Sponsor
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Who can join
18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In cancer patients, prognostic markers are needed to improve the management and clinical course of both the cancer itself and surgery therefor. Elevated systemic inflammatory markers are associated with morbidity and mortality in most cancer types. In this study, the investigators aimed to determine the prognostic value of inflammatory markers such as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and lymphocyte to monocyte ratio (LMR) in patients undergoing cytoreductive surgery for ovarian cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06629831
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer
Currently open trials in the same condition.
- NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
- NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
- NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
- NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Bakirkoy Dr. Sadi Konuk Research and Training Hospital trials
Trials by the same sponsor.
- NCT07425379 — Prehabilitation in Breast Cancer Surgery · NA · not yet recruiting
- NCT07367321 — Comparison of Onlay Mesh Repair and Sublay Mesh Repair in Umbilical Hernia Surgery · NA · not yet recruiting
- NCT07077629 — Geriatric Patients Undergoing Gynaecological Cancer Surgery · completed
- NCT07000461 — Transcranial Doppler as a Predictor of Postoperative Cognitive Dysfunction Following Cardiopulmonary Bypass · recruiting
- NCT07295405 — Water Temperature and Bowel Cleansing Quality · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06629831 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bakirkoy Dr. Sadi Konuk Research and Training Hospital
- Last refreshed: 9 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06629831.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing